搜索:
教授
姜世勃
发表时间:2013-12-16 阅读次数:8696次

姓名:姜世勃 博士
职称:教授
E-MAIL: shibojiang@fudan.edu.cn
WWW: http://medicine.fudan.edu.cn/Pathogen/show.aspx?info_lb=23&flag=2&info_id=38

 

 

 

研究方向
1.研究I型包膜病毒入侵靶细胞的机制
2.研发抗艾滋病病毒(HIV)的药物和疫苗
3.研发可预防HIV性传播的杀微生物剂
4.研发抗严重急性呼吸综合征冠状病毒(SARS-CoV)的药物和疫苗
5.研发抗中东呼吸综合症冠状病毒(MERS-CoV)的药物和疫苗
6.研发抗高致病性流感病毒的疫苗和药物
7.研发可防控人乳头瘤病毒(HPV)感染和宫颈癌的生物制剂和药物
8.研发抗呼吸道合胞病毒(RSV)的药物
9.研发抗埃博拉病毒(EBOV)的药物
10.研发抗尼帕病毒(NiV)的药物
11.研发抗寨卡病毒(ZIKV)的药物和疫苗

重要学术贡献
主要从事抗病毒(HIV、SARS-CoV、MERS-CoV、RSV、HPV、IAV、EBOV、ZIKV等)药物及疫苗研究。在九十年代初发现了第一个高效的抗HIV C-多肽 -- SJ-2016, 其美国发明专利(USP 5,444,044)转让给美国的Trimeris药物公司,其与罗氏药物公司联合开发出国际上第一个基于“病毒进入抑制剂”(Virus entry inhibitor)的抗HIV多肽药物 -- 恩夫韦肽(Enfuvirtide,T-20)。因此,该发现开辟了研发病毒进入抑制剂和抗病毒多肽药物的新领域。此后, 他的团队又发现了抗SARS-CoV、MERS-CoV、和ZIKV的多肽, 并研发出安全有效的抗SARS和MERS候选亚单位疫苗。他是国际上最早参与研发预防HIV性传播的杀微生物剂(Microbicides)的研究人员之一, 在九十年代中发现一些经过酸酐修饰的蛋白能有效地抑制HIV和HSV-2的感染, 其中一个酸酐修饰蛋白 -- JB蛋白还可高效地抑制HPV感染。其专利转让给山西锦波生物医药股份有限公司开发出“抗HPV生物蛋白敷料”,经山西省药监局批准后已在500多家医院使用,可有效地抑制HPV在宫颈部位的感染,有望能降低宫颈癌的发生率。

荣誉与获奖
2013     中华预防医学会科学技术奖二等奖 (第八名)
2013    复旦大学基础医学院“杰出贡献奖”和“杰出教授奖”
2013     北京市科学技术奖三等奖 (第十一名)
2015    上海教育年度十大新闻人物奖

国内外学术团体任职
1988-pres    美洲华人生物科学学会会员(终身会员)
2000-pres    国际抗病毒研究学会会员
2000-pres    国际艾滋病学会会员
2010-pres    美国微生物学会会员

学术刊物编委或受邀审稿
2005-今        编辑顾问(Editorial Consultant),The Lancet
2011-今        评审编辑(Review Editor),Emerging Microbes and Infection
2010-今        科学编辑(Scientific Editor),PloS ONE
2010-今        编委(Editorial board member),Retrovirology
2015-今        编委(Editorial board member),Biochim Biophys Acta
2010-今        编委(Editorial board member),Microbes and Infection
已受邀为70多家英文SCI杂志(如 Science, Science Translational Medicine, Science Advance, Nature Medicine, Nature Review Microbiology, Nature Review Drug Discovery, Nature Communication, Nature Microbiology, Lancet, Lancet Infectious Diseases, Lancet Global Health, Lancet Respiratory Medicine, PNAS等)审稿,每年审稿50篇以上。

校内学术机构任职
1.复旦大学学术委员会委员
2.上海医学院学术委员会委员
3.基础医学院教授委员会委员
4.基础医学院高级职务聘任学术委员会委员
5.基础医学院高级职务聘任教授会议成员
6.基础医学院学位评定分委员会委员
7.复旦大学病原微生物研究所所长
8.复旦大学医学分子病毒学教育部/卫计委重点实验室科研委员会主任委员
9.复旦大学医学分子病毒学教育部/卫计委重点实验室副主任
10.复旦大学基础医学院病原生物系副主任

受邀学术报告
2017    A chemically modified milk protein for preventing HIV sexual transmission and treating HPV infection. 5th International Conference on HIV/AIDS, STDs and STIs, Las Vegas, Nevada, USA.
2017    A protein-based viral entry inhibitor against Ebola viruses, Ameican Sociaty of Virology (ASV) 2017. Medison, Wisconsin, USA.
2017    Advances in Developing Vaccines and Therapeutics against MERS-CoV. 5th isirv-AVG Conference. Prevention and Treatment of RVIs: Antivirals, Traditional Therapies and Host-Directed Interventions, Shanghai, China.
2016    Development of a chemically modified protein-based microbicides for prevention of HIV sexual transmission and treatment of HPV infection. International Conference on STDs and HIV, Dubai, United Arab Emirates.
2015    Development of viral entry inhibitor-based prophylactics for prevention of MERS-CoV. MERS-CoV. MERS Vaccine Development Workshop. Ministry of Health, Saudi Arabia, Riyadh, Saudi Arabia.
2015    Virus fusion/entry inhibitors against Ebola viruses. 34th Annual Meeting of the American Sociaty of Virology (ASV2015), London, Ontario, Canada.
2014    Development of HA- and M2e-based H5N1 Influenza Vaccines. International Symposium on vaccines against Antigenically Variable Viruses (VAAVV). Ames, IA, USA.
2014    Development of vaccines and therapeutics for prevention and treatment of MERS. XIIIth International Nidovirus Symposium. Salamanca, Spain.
2014    Development of Vaccines and Therapeutics against MERS-CoV. 2014 ASM Biodefense and Emerging Diseases Research Meeting. Washington DC, USA.
2013    Peptide and small molecule HIV fusion inhibitors targeting gp41. EMBO Workshop on Cell-Cell Fusion, Ein Gedi, Israel.
2012    HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. 14th Annual International Meeting of IHV, Baltimore, USA.
2012    Research and development of HIV entry inhibitors targeting gp41 pocket. 22nd Annual Meeting of the Society for Virology, Haus der Technik in Essen, Germany.

发表论文
已发表402篇SCI论文(总影响因子为1,952,篇均4.9),详细请查如下链接:http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48247255/?sort=date&direction=descending

1.Yu, Y., Deng, Y.Q., Zou, P., Wang, Q., Dai, Y., Yu, F., Du, L., Zhang, N.N., Tian, M., Hao, J.N., Meng, Y, Li, Y., Zhu, X., Woo, J.F.W., Yuen, K.Y., Qin, C.F.*, Jiang, S.*, Lu, L.* (2017). A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat. Commun. 8, 15672. IF=12.124.
2.Yu, F.#, Song, H.#, Wu, Y.#, Chang, S.Y., Wang, L., Xia, S., Hong, B., Li, W., Wang, C., Khurana, S., Feng, Y., Wang, Y., Sun, Z., He, B., Min, J.Y., Golding, H., J. X., Lu, L., Jiang, S., Dimiktrov, D., Ying, T.* (2017). A potent germline-like human monoclonal antibody targeting a novel pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe. 22(4):471-483.e5. IF=14.946.
3.Du, L., Tai, W., Yang, Y., Zhao, G., Zhu, Q., Sun, S., Liu, C., Tao, X., Tseng, C.T.K., Perlman, S., Jiang, S.*, Zhou, Y.*, Li, F.*. (2016). Measuring the neutralizing immunogenicity indexes of epitopes as a basis for the rational design of MERS-CoV vaccines. Nat. Commun. 7:13473. IF=12.124.
4.Lai, W.#, Wang, C.#, Yu, F.#, Lu, L., Wang, Q., Jiang, X., Xu, X., Zhang, T., Wu, S., Zhang, Z., Dong, F., Cai, L., Jiang, S.*, Liu, K.* (2016). An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chem. Sci. 7: 2145-2150. IF=9.144.
5.Ying, T.*, Prabakaran, P., Du, L., Feng, Y., Wang, Y., Shi, W., Wang, L., Jiang, S., Dimitrov, D.S, Zhou, T.* (2015). A novel critical role of junctional and allele-specific amino acids for the mechanism of MERS-CoV neutralization by an exceptionally potent germline-like IGHV1-69 lineage antibody. Nat. Commun. 6:8233. IF=12.124.
6.Wang, C.#, Lai, W.#, Yu, F, Zhang, T., Lu, L., Jiang, X., Zhang, Z., Xu, X., Yu, B., Jiang, S.*, Liu, K.* (2015). De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for the developingment of antiviral therapeutics. Chem. Sci. 6, 6505–6509. IF=9.211.
7.Lu, L., Liu, Q., Zhu, Y., Chan, K.H., Qin, L., Li, Y., Wang, Q., Chan, J., Du, L., Yu, F., Ma, C., Ye, S., Yuen, K.Y., Zhang, R., Jiang, S.* (2014). Structure-based discovery of Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitor. Nat. Commun. 5:3067. IF=12.124.
8.Yang, Y., Du, L., Liu, C., Wang, L., Ma, C., Baric, R.S., Jiang, S.*, Li, F.* (2014). Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Nat. Acad. Sci. USA. 111(34):12516-21. IF=9.737.
9.Zirafil, O., Kim, K.A., Roan, N.R., Klugel, S.F., Müller, J.A., Jiang, S., Mayer, B., Greene, W.C., Kirchhoff, F., Münch, J.* (2014). Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. Sci. Transl. Med. 6(262):262ra157. IF= 14.414
10.Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B., Jiang, S.* (2009). Development of vaccines and therapeutics targeting the spike protein of SARS-CoV. Nature Rev. Microbiol. 7, 226-236.
11.He, Y.*, Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., Dai, Q.* (2008). Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Nat. Acad. Sci. USA. 105, 16332-16337. IF=9.737.
12.Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., Meyer. B., Wilhelm, D., Lu, H., Jing, W., Jiang, S., Forssmann, W., Kirchhoff, F.* (2007). Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129, 263-275. IF=30.410.
13.Stone, A.*, and Jiang, S. (2006). Microbicides: stop HIV at the gate. Lancet 368, 431-433. IF=47.831.
14.Jiang, S.*, Liu, S., and Stone, A. (2006). China needs safe and effective microbicides for preventing the sexual transmission of HIV. Lancet Infect. Dis. 6, 681-682. IF=19.864.
15.Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C.R., Xiong, H., Farmar, J., Debnath, A.K., Tien, P., and Jiang, S.* (2004). Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 363, 938-947. IF=47.831.
16.Jiang, S.* (1997). HIV-1˗ co-receptors binding. Nature Med. 3, 367-368. IF=29.886.
17.Neurath, A.R.*, Jiang, S., Strick, N., Lin, K., Li, Y.-Y., and Debnath, A.K. (1996). Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nature Med. 2, 230-234. IF=29.886.
18.Jiang, S.*, Lin, K., Strick, N., and Neurath, A.R. (1993). HIV-1 inhibition by a peptide. Nature 365, 113. IF=40.137.
19.Jiang, S.*, Lin, K. and Neurath, A.R. (1991). Enhancement of human immuno-deficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174, 1557-1563. IF=11.991.
20.Jiang, S., Persechini, P.M., Zychlinsky, A., Liu, C.C., Perussia, B., and Young, J.D.-E.* (1988). Resistance of cytolytic lymphocytes to perforin-mediated killing. Lack of correlation with comple¬ment-associated homolo¬gous species restriction. J. Exp. Med. 168, 2207-2219. IF=11.991.

学术专著
1.Lu, L., Jiang, S.* (2014). FUSION. In Encyclopedia of AIDS. Ed. Thomas J. Hope, Mario Stevenson, Douglas Richman, Springer Publisher, 2014.
2.姜世勃, 陆路。第二十章, 人类免疫缺陷病毒。《医学微生物学》,主编:徐志楷等,全国高等学校第二轮医学研究生规划教材,人民卫生出版社,北京,2014年6月第一版。

申请或授权专利
已申请美国专利32项(授权22项)和中国及PCT专利43项(授权12项),以下是已经成功转让的授权专利:

1.Jiang, S., Lin, K., and Neurath, A.R. Synthetic peptides as inhibitors of HIV-1. US 5,444,044. Filed March 26, 1992; Issued August 22, 1995.
2.Jiang, S., Lin, K., and Neurath, A.R. Synthetic peptides as inhibitors of HIV-1 (continuation patent). US 5,840,843. Filed June 7, 1995; Issued on November 24, 1998.
3.Jiang, S., and Debnath, A.K. Screening of antiviral compound targeted to the HIV-1 gp41 core structure. US 6,596,497¬. Filed March 14, 2000. Issued July 22, 2003.
4.Jiang, S., Pan, C. Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors. US 7,919,101. Filed August 13, 2008. Issued April 5, 2011.
5.Jiang, S., Pan, C. Bifunctional molecules for inhibiting HIV entry. US 8,828,931. Filed May 3, 2000. Issued September 9, 2014.
6.Jiang, S., Pan, C., Lu, L. Bifunctional molecules for inactivating HIV and blocking HIV entry. US 8,828,932. Filed May 3, 2010. Issued September 9, 2014.
7.杨霞,姜世勃,陆路。一种可用于预防和控制人乳头瘤病毒感染的生物制剂及其制备方法。中国专利号:ZL 201210066696.9,申请日:2012-3-14,授权日:2013-08-07.

 

Copyright 2012 ◎ 复旦大学基础医学院
地址:上海市医学院路138号 电话:021-54237900 传真: 021-64179832